User Notice: The old Support number is no longer in use. To reach Support please call +44 (0) 203 8794 460

Share Name Share Symbol Market Type Share ISIN Share Description
Omega Diagnostics Group Plc LSE:ODX London Ordinary Share GB00B1VCP282 ORD 4P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 10.10 2,992 08:00:00
Bid Price Offer Price High Price Low Price Open Price
9.70 10.50 10.10 10.10 10.10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 13.55 -6.91 -0.40 13.0
Last Trade Time Trade Type Trade Size Trade Price Currency
09:39:56 O 2,992 9.72 GBX

Omega Diagnostics (ODX) Latest News

More Omega Diagnostics News
Omega Diagnostics Takeover Rumours

Omega Diagnostics (ODX) Share Charts

1 Year Omega Diagnostics Chart

1 Year Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

Intraday Omega Diagnostics Chart

Intraday Omega Diagnostics Chart

Omega Diagnostics (ODX) Discussions and Chat

Omega Diagnostics Forums and Chat

Date Time Title Posts
15/7/201923:24Omega Diagnostics - nicely poised for significant growth1,623
01/8/201708:17Omega Diagnostics1,774

Add a New Thread

Omega Diagnostics (ODX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
08:39:589.722,992290.70O
2019-07-15 13:20:099.722,934285.07O
2019-07-15 13:10:429.7219118.56O
View all Omega Diagnostics trades in real-time

Omega Diagnostics (ODX) Top Chat Posts

DateSubject
16/7/2019
09:20
Omega Diagnostics Daily Update: Omega Diagnostics Group Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker ODX. The last closing price for Omega Diagnostics was 10.10p.
Omega Diagnostics Group Plc has a 4 week average price of 9.50p and a 12 week average price of 9.50p.
The 1 year high share price is 18.10p while the 1 year low share price is currently 9.50p.
There are currently 133,307,010 shares in issue and the average daily traded volume is 17,567 shares. The market capitalisation of Omega Diagnostics Group Plc is £13,464,008.01.
03/6/2019
22:27
upomega: Lik As far as I can determine the bod are paid the going rate. Maybe if they could take a pay cut and accept an options package in return.that would at least give a good incentive to drive the share price forward. On a positive if things are on track Nigeria have finished field trials so hopefully an order for visetect will follow shortly.the only worry there is how the company receives payment from production.
01/6/2019
23:58
likitorma: Directors' remuneration in 2018: Shepherd: £218k Hurbinson: £151k Grewal: £142k King: £181k All this while share price keeps crashing. Time to call a day on them. The recent raise adds up nicely to the board salary.
16/5/2019
22:37
upomega: Surely the house broker would have been pushing the share price up in some way prior to a placing.if it does happens now then lets hope we are all invited to participate in it at a advantageous price
15/5/2019
10:34
upomega: The sad fact is he probably is. I wouldn't be surprised in seeing a placing where the largest two holders acquire most of the discounted shares with himself and other directors buying in at a nice discounted price. Hence why he didn't invest on joining the company I have already been in touch with the registrar voicing my concern as to what appears as manipulation of the share price. This morning is another good example.
08/5/2019
20:58
barrywhit: upomega, Investors sell for a variety of reasons, most see a better opportunity elsewhere. ODX is a slow burn, by year end we will know if CD4 is going to take off commercially...I am sure the company are just as disappointed with the share price as we are...
15/2/2019
01:01
barrywhit: Upomega, This company has never had fluidity in it’s shares, small amounts of trades normally move the share price either way. With the delays in bringing CD4 to market, investors have lost confidence and moved on. It’s a slow burn with ODX, there are better trading opportunities elsewhere. There are a few Longterm PI’s still holding along with 3 main Holders only, so until the market believes ODX can bring CD4 to commercialisation we are where we are...
08/2/2019
23:14
barrywhit: upomega, Not really been enough P.I BUYS to lift the share price, wouldn't be surprised to see Sneller has been increasing his stake in the last couple of months.. The company has lost a lot of their Private Investors over the last 12 months, and it is P.I's who lift the share price, not Sneller or Mills they just sit there taking all the sells...or add on equity raising...
31/1/2019
15:24
hyperboreus: I personally do not care too much about the day to day movement in the share price as others seem to do but it is quite apparent that there is a bit of selling going on today so clearly some holder(s) have decided they have had just had enough despite what was on the face of it a seemingly positive update only a few days ago. Just spent some time looking back through the archives to check when the VISITECT® CD4 CE-Mark announcement was and it may be surprising to some that it was over 14 months ago now when the following statement was made: 'The successful completion of the CE-Mark process means these tests, which indicate whether a person's CD4 count is higher or lower than 350 cells/mm³, are available for general sale through business to business channels in countries not requiring individual product registration. The technical file forms the basis of the additional regulatory approval the Company will seek through the World Health Organisation Prequalification programme which assesses in vitro diagnostics tests for priority diseases and their suitability for use in resource-limited settings. A successful completion of this process will enable Omega to become eligible for public sector procurement. The Company anticipates that this process is likely to be completed during the second half of the next financial year.' It is now just 2 months to this end of the financial year end (31 March 2019). To be fair to ODX since then guidance has changed regarding the cut-off levels on a number of occasions, but surely you would have thought that shareholders have a right to know how the regulatory process is progressing? On 6 August 2018 when the final results were announced it was stated that: 'The jewel in our crown, we believe, is our CD4 test for the monitoring of the immune status of people living with HIV at the point of care. We were able to CE mark and launch the 350-cut-off level during the year. The uptake of the test is dependent upon individual country registration. The bigger CD4 prize is being able to reach the 200-cut-off level which we hope we will be able to achieve by the end of the final quarter of this calendar year. It is our belief that the availability of this test will expand the addressable market and have the support of several NGOs which will follow WHO guidance on the matter. In overall terms we anticipate registering the test in over 100 countries over the next four years if we can apply the maximum available resource to the process of registration. The main gating item is the availability of personnel to undertake this process which, if one assumes an individual can undertake between six and eight registrations per year gives you an idea of scale. It is our intention, subject to securing the CE marking of the 200-cut-off level, to apply the maximum available resource.' The interims last December disclosed that distribution agreements had been signed with 11 countries and negotiations were ongoing with a further 5 so the enormity of the task ahead is very clear. I have no idea what is in the distribution agreements already signed but you would hope that it might fast track the lower 200 cut-off test as and when it is ready to go. Not wishing to be mischievous or make this personal in any way but our former Non-executive Chairman did make the following statement only last August: 'Ultimately, we are judged by our results and it may end up being a rather circuitous route to success, but I do believe that after many years of famine shareholders will see some bread in their basket by this time next year. The key thereafter will be to replenish that basket. I am confident we can achieve both.' As things stand right now I would suggest that there are just a few crumbs in the basket and with only 8 months to go I personally fail to see how any meaningful bread will appear without a disposal of some kind. Finally I would like to thank NXC for being so candid with his thoughts on this thread and elsewhere. I genuinely do wish you all the very best in the future and just for the record one of the major reasons I first invested in ODX quite some time ago now was your presence on the board, all true! 👍
23/12/2018
15:35
gwr7: Hyperboreus6 Apr '18 - 10:53 - 589 of 996 "Another 8 months away yet but Messrs Evans, Shepherd and Harbinson each have options granted on 10 December 2008 with an exercise price of 19p which expire on 10 December 2018. No idea what is likely to propel the share price north of 19p in the short term, just shows how their expectations of how Omega would perform over the last 10 years have just not materialised. In a perverse way I almost hope that the share price doesn't rise too much this year as they do not deserve to profit from them in my opinion, that is my 'gripe of the day' out of the way now!" Well you got your wish Mr. H and the positive trading update on 10th October didn't push the share price above 19p before their options expired. Colin King, CEO of Omega commented: "We are making great progress implementing our revised strategic direction and the narrower focus is already starting to deliver in our three key areas. Overall, we believe the actions we are taking will ultimately deliver shareholder value both in the short and long term." How long is the short term? Have a good Christmas.
17/12/2018
08:55
hyperboreus: Well the first tranche of options have come and gone: Https://www.investegate.co.uk/omega-diagnostics-gp--odx-/rns/director-pdmr-shareholding/200812121548210744K/ If that isn't an obvious sign of failure to increase shareholder value over the last 10 years I don't know what is, however in fairness to the three directors involved they could have exercised their respective options at various times during the decade. Interesting coincidence that David Evans resigned on the exact day (10 December 2018) that the options lapsed. Jag Grewal the Group Sales & Marketing Director (who rarely receives any negative comment on here it appears for some mystifying reason to me) has a few @ 13.25p which expire in August 2021: Https://www.investegate.co.uk/omega-diagnostics-gp--odx-/rns/director-pdmr-shareholding/201108151405213769M/ A few more to various individuals expire in 2022 .....but the stand out shall we say 'very generous' one was granted to our current albeit stand-in Non-Exec Chairman Bill Rhodes which expire on American Independence Day 2023: Https://www.investegate.co.uk/omega-diagnostics-gp--odx-/rns/grant-of-options/201307041122116179I/ Just what he has brought to the table to justify that award is not immediately obvious to me at this juncture. I am not trying to be mischievous or overly negative here but the bottom line is that the current and ex ODX Board members have clearly not delivered on their various strategies over the past decade and given the current share price the market appears unconvinced they will any time soon. Have a lovely festive season everyone! 🎄
Omega Diagnostics share price data is direct from the London Stock Exchange
Your Recent History
LSE
ODX
Omega Diag..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190716 12:17:04